Literature DB >> 863901

Purification and properties of a plasminogen activator from pig heart.

E R Cole, F W Bachmann.   

Abstract

An improved procedure is described for the purification of plasminogen activator from pig heart. The initial purification steps were similar to these described previously (Bachmann, F., Fletcher, A. P., Alkjaersig, N., and Sherry, S. (1964) Biochemistry 3, 1578--1585). Use of a novel extraction medium containing EDTA, cysteine, and 2,3-dimercaptopropanol-1 facilitated the removal of large amounts of inert proteins prior to gel filtration on Bio-Gel P-150. The final product had a specific activity of 120,000 to 160,000 CTA units/mg of protein (CTA, Committee on Thrombolytic Agents of the National Heart Institute). Total purification over pig heart was 25,000 to 30,000-fold, average recovery compared to the initial extract was 6 to 8%. Polyacrylamide gel electrophoresis revealed a major and two minor components. The molecular weight of the activator determined by gel filtration was 51,500 +/- 3,400 for the major activity component and 48,000 for a minor component which was partially separated from the major peak in eight of nine chromatography runs. A gamma-globulin fraction of antiserum against purified activator neutralized the biological activity of the activator on fibrin plates. Immunoelectrophoresis of gel-filtered activator revealed only one anodic component.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 863901

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.

Authors:  S S Husain; B Lipinski; V Greuwich
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

2.  A novel leupeptin-sensitive serine endopeptidase present in normal and malignant rat mammary tissues.

Authors:  I Eto; M D Bandy
Journal:  Mol Cell Biochem       Date:  1990-04-18       Impact factor: 3.396

3.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

Authors:  C Korninger; O Matsuo; R Suy; J M Stassen; D Collen
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

4.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.

Authors:  D Collen; J M Stassen; M Verstraete
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

5.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.